Evidence map›Paper›PMID 24101301›Full record

ArticleMolecular pharmacology2013

Indistinguishable synaptic pharmacodynamics of the N-methyl-D-aspartate receptor channel blockers memantine and ketamine.

Christine M Emnett, Lawrence N Eisenman, Amanda M Taylor, Yukitoshi Izumi, Charles F Zorumski, Steven Mennerick

Registry-linked trialOpen access · bronzeAbstract readComparative Study
In one paragraph

Article in Molecular pharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01179009 (A Safe Ketamine-Based Therapy for Treatment Resistant Depression), which is not on this map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01179009 nacompletednot on this map

A Safe Ketamine-Based Therapy for Treatment Resistant Depression

TypeinterventionalSponsorWashington University School of MedicineRan2012 to 2015Enrolled20ConditionsDepressive Disorder, Treatment-ResistantArmsKetamine, Clonidine, placebo
3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 59 citations in OpenAlex.

  1. Trial
  2. Ninety-six hour ketamine infusion with co-administered clonidine for treatment-resistant depression: A pilot randomised controlled trial.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry · 2016
    Trial
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Positive Allosteric Modulation as a Potential Therapeutic Strategy in Anti-NMDA Receptor Encephalitis.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2018
    Article
  19. Memantine and Ketamine Differentially Alter NMDA Receptor Desensitization.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2017
    Article
  20. New targets for rapid antidepressant action.Progress in neurobiology · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Christine M EmnettGraduate Program in Neuroscience (C.M.E.), Washington University, and Departments of Psychiatry (C.M.E., A.M.T., Y.I., C.F.Z., S.M.), Neurology (L.N.E.), Anatomy and Neurobiology (C.F.Z., S.M.), and Taylor Family Institute for Innovative Psychiatric Research (Y.I., C.F.Z., S.M.), Washington University School of Medicine, St. Louis, Missouri.
Lawrence N Eisenman
Amanda M Taylor
Yukitoshi Izumi
Charles F Zorumski
Steven Mennerick
Taylor Family Institute for Innovative Psychiatric ResearchWashington University in St. Louis · US

Funding

Systems and Molecular Neurobiology Training ProgramT32GM008151 · NIGMS · WASHINGTON UNIVERSITY · PI SNYDER, LAWRENCE H · 1985 to 2019
$6.5M
CONTROL OF SYNAPTIC GLUTAMATE RELEASER01MH078823 · NIMH · WASHINGTON UNIVERSITY · PI MENNERICK, STEVEN J · 2006 to 2015
$3.2M
MODULATION OF HIPPOCAMPAL SYNAPTIC PLASTICITYR01MH077791 · NIMH · WASHINGTON UNIVERSITY · PI ZORUMSKI, CHARLES F · 2007 to 2013
$2.4M
NIAAA NIH HHS AA01743NIGMS NIH HHS T32 GM008151NIGMS NIH HHS T32GM008151NIMH NIH HHS MH077791NIMH NIH HHS MH078823NIMH NIH HHS R01 MH077791NIMH NIH HHS R01 MH078823
6 · The paper itself

Abstract

Memantine and ketamine, voltage- and activation-dependent channel blockers of N-methyl-d-aspartate (NMDA) receptors (NMDARs), have enjoyed a recent resurgence in clinical interest. Steady-state pharmacodynamic differences between these blockers have been reported, but it is unclear whether the compounds differentially affect dynamic physiologic signaling. In this study, we explored nonequilibrium conditions relevant to synaptic transmission in hippocampal networks in dissociated culture and hippocampal slices. Equimolar memantine and ketamine had indistinguishable effects on the following measures: steady-state NMDA currents, NMDAR excitatory postsynaptic current (EPSC) decay kinetics, progressive EPSC inhibition during repetitive stimulation, and extrasynaptic NMDAR inhibition. Therapeutic drug efficacy and tolerability of memantine have been attributed to fast kinetics and strong voltage dependence. However, pulse depolarization in drug presence revealed a surprisingly slow and similar time course of equilibration for the two compounds, although memantine produced a more prominent fast component (62% versus 48%) of re-equilibration. Simulations predicted that low gating efficacy underlies the slow voltage-dependent relief from block. This prediction was empirically supported by faster voltage-dependent blocker re-equilibration with several experimental manipulations of gating efficacy. Excitatory postsynaptic potential-like voltage commands produced drug differences only with large, prolonged depolarizations unlikely to be attained physiologically. In fact, we found no difference between drugs on measures of spontaneous network activity or acute effects on plasticity in hippocampal slices. Despite indistinguishable synaptic pharmacodynamics, ketamine provided significantly greater neuroprotection from damage induced by oxygen glucose deprivation, consistent with the idea that under extreme depolarizing conditions, the biophysical difference between drugs becomes detectable. We conclude that despite subtle differences in voltage dependence, during physiologic activity, blocker pharmacodynamics are largely indistinguishable and largely voltage independent.

Indexed as

AnimalsExcitatory Postsynaptic PotentialsFemaleGlucoseHEK293 CellsHippocampusHumansIn Vitro TechniquesIon Channel GatingKetamineMaleMemantineNerve NetNeuronal PlasticityNeuronsNeuroprotective AgentsGlucoseKetamineMemantineNeuroprotective AgentsOxygenReceptors, N-Methyl-D-Aspartate

Identifiers

PMID24101301
PMCPMC3834148
OpenAlexW2106396641

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.